$0.00

(%)
Live
Previous Close

$

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$194.7 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for managemen...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise--

Related tickers: VERU.

Read Full Article

4 analysts have shared their evaluations of Veru (NASDAQ:VERU) during the recent three months, expressing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $3.25, along with a high estimate of $5.00 and a low estimate of $2.00. This current average has decreased by 27.78% from the previous average price target of $4.50. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Veru by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Yi Chen HC Wainwright & Co. Raises Buy $3.00 $2.00 Leland Gershell Oppenheimer Lowers Outperform $5.00 $7.00 Gary Nachman Raymond James Announces Outperform $3.00 - Yi Chen HC Wainwright & Co. Maintains Buy $2.00 - Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veru. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Delving ...Full story available on Benzinga.com

Related tickers: VERU.

Read Full Article
Trending Tickers
AMBO

XASE

$0.00
(%)
LASE

XNAS

$0.00
(%)
SMFL

XNAS

$0.00
(%)
BFRG

XNAS

$0.00
(%)
MLGO

XNAS

$0.00
(%)